Senolytics and Chronic Inflammation: Reversing Inflammaging
Expert Summary
Inflammaging (chronic age-related systemic inflammation) contributes to virtually every major chronic disease of aging: cardiovascular disease, type 2 diabetes, neurodegeneration, cancer, sarcopenia, and osteoporosis. Senescent cells are one of the primary sources of inflammaging via persistent SASP secretion. Reducing senescent cell burden measurably reduces systemic inflammatory markers.
Key Facts
- SASP as primary inflammaging driver: Studies estimate that senescent cells contribute 20–40% of systemic IL-6 production in aged individuals — making them among the most significant sources of chronic inflammatory signaling.
- Clinical evidence for IL-6 reduction: D+Q treatment in IPF patients reduced circulating IL-6 by 24–40%, MMP-3 by 27–34%, and MMP-9 by 37%. These are clinically meaningful reductions with implications for cardiovascular and metabolic risk.
- CRP and hsCRP response: hsCRP (a sensitive inflammatory marker used for cardiovascular risk stratification) consistently decreases after senolytic cycling in clinical experience. Users on monthly fisetin+quercetin protocols report reductions in hsCRP from high-risk (>3 mg/L) to moderate or low-risk ranges.
- NF-κB pathway: Both senescent cells' SASP production and quercetin/fisetin supplementation converge on NF-κB. Senolytics reduce NF-κB activity by eliminating the cells most heavily driving NF-κB-dependent inflammatory gene expression.
- Inflammaging disease connections: IL-6 from SASP drives: hepatic acute phase response (CRP, fibrinogen) → cardiovascular risk; insulin resistance (T2D, metabolic syndrome); cognitive decline (IL-6 crosses BBB and drives neuroinflammation); muscle wasting (IL-6 activates muscle protein catabolism).
- Dose-response of anti-inflammatory effect: Greater senescent cell clearance → greater SASP reduction → greater inflammaging reduction. More frequent and/or potent senolytic protocols produce proportionally larger inflammatory marker reductions.
Recommended Products
Frequently Asked Questions
How quickly do inflammatory markers fall after senolytics?
In clinical trials, SASP-related markers (IL-6, MMP-3) begin declining within the first week post-treatment. The reduction continues over 2–4 weeks as dead senescent cells are cleared by phagocytes. hsCRP typically decreases within 2–4 weeks.
Can senolytics normalize CRP to below 1 mg/L?
In individuals with CRP elevated primarily from senescent cell SASP (rather than active infection, autoimmune disease, or other causes), senolytics can be sufficient to bring CRP to optimal range. Results depend on baseline senescent cell burden and the comprehensiveness of the senolytic protocol.
Scientific References
- Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018. PMID: 29988130
- Franceschi C et al. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology. 2018. PMID: 30065258